Highest-materiality recent filing
NeuroOne files prospectus to sell up to $13.4M in common stock via ATM program with JonesTrading
Updated prospectus supplement filed June 12, 2026 for at-the-market offering of up to $13.4M of common stock.
NeuroOne restates Q1 FY2026 results due to revenue recognition error; reaffirms FY2026 guidance
Revenue overstated by ~$0.5M, net loss understated by ~$0.3M for quarter ended March 31, 2026.
NeuroOne Q2 product revenue up 72% to $2.4M; net loss narrows to $2.1M
Product revenue $2.4M (+72% YoY); no license revenue vs $3.0M in prior year first half.
NeuroOne regains Nasdaq compliance as bid price holds above $1 for 10 days
Received Nasdaq deficiency letter on May 6, 2025 for bid price below $1 for 30 consecutive days.
NeuroOne to effect 1-for-6 reverse stock split to regain Nasdaq compliance
Board approved 1-for-6 reverse stock split, effective 5:00 p.m. ET on April 15, 2026.
NeuroOne shareholders approve reverse stock split and 1.5M share increase in equity plan
Shareholders approved reverse stock split at ratio of 1-for-2 to 1-for-15; board to determine final ratio.
NeuroOne Q1 net loss $1.4M; guides FY26 product revenue at least $10.5M
Q1 product revenue $2.9M (down 12% YoY, but up 5.5% sequentially from Q4 FY25).
NeuroOne reports Q4 product revenue of $2.7M (+907% YoY); full-year loss narrows 71%
Product revenue $2.7M in Q4 FY2025, up 907% YoY; full year product revenue $9.1M, up 163% YoY.
NeuroOne Medical receives Nasdaq extension to May 4, 2026 to regain $1.00 bid price compliance
Nasdaq granted a 180-day extension until May 4, 2026 for minimum bid price compliance.
NeuroOne reports preliminary FY2025 product revenue of $9.1M, up 163% from $3.5M in FY2024
Preliminary unaudited FY2025 product revenue $9.1M, a record; FY2024 was $3.5M.
NeuroOne receives FDA 510(k) clearance for OneRF Trigeminal Nerve Ablation System
FDA 510(k) clearance granted for OneRF Trigeminal Nerve Ablation System.
NeuroOne Q3 revenue up 105% to $1.7M; net loss narrows to $1.5M; FY25 guidance reaffirmed
Product revenue $1.7M, up 105% YoY; gross margin 53.9% (vs 34.1%).
NeuroOne Q2 net loss narrows to $2.3M; gross margin up to 55.6%
Q2 product revenue $1.4M flat YoY; H1 product revenue up 98% to $4.7M.
NeuroOne receives Nasdaq deficiency notice for bid price below $1.00
Closing bid price was below $1.00 for 30 consecutive business days; 180-day cure period ends Nov. 3, 2025.
NeuroOne raises $8M in underwritten public offering of 16M shares at $0.50/share
Offered 16,000,000 shares at $0.50 per share; underwriter option for additional 2,400,000 shares.
NeuroOne stockholders approve 2025 Equity Incentive Plan and reverse stock split
Approved 2025 Equity Incentive Plan authorizing up to 3M new shares plus returning shares from prior plan.
NeuroOne Q1 FY2025 revenue $6.3M, net income $1.8M; reaffirms FY guidance
Product revenue $3.3M (+235% YoY); license revenue $3.0M from expanded Zimmer Biomet deal.
NeuroOne regains Nasdaq compliance; reports record preliminary Q1 revenue of $6.2M
Received Nasdaq letter on Feb 3, 2025 confirming cure of bid price deficiency; hearing cancelled.
NeuroOne reports preliminary Q1 FY2025 revenue of $6.2M, up from $1.0M YoY
Preliminary unaudited Q1 FY2025 total revenue $6.2M vs $1.0M in Q1 FY2024.
NeuroOne receives Nasdaq delisting determination for bid price non-compliance; intends to appeal
Received delisting determination from Nasdaq on Jan 8, 2025 for continued non-compliance with $1.00 minimum bid price rule.
NeuroOne FY2024 product revenue $3.5M (+77%); FY2025 guidance $8-10M (+132-190%)
Product revenue FY2024 $3.5M (+77% YoY); net loss $12.3M vs $11.9M prior year.
NeuroOne expands Zimmer Biomet distribution deal for OneRF Ablation System; $3M upfront
Zimmer Biomet gets exclusive US and certain OUS distribution rights for OneRF Ablation System.
Product revenue $826K in Q3 FY2024 vs $630K in Q3 FY2023 (+31%); net loss $2.8M vs $3.5M.
NeuroOne raises ~$2.65M in private placement and secures $3M debt facility
Private placement of 2,944,446 shares and warrants for 2,208,333 shares at $0.90/unit, gross ~$2.65M.
NeuroOne receives Nasdaq delisting notice for bid price below $1.00 for 30 days
Closing bid price of common stock below $1.00 for 30 consecutive business days triggered Nasdaq minimum bid price deficiency.
NeuroOne Q2 FY2024 product revenue triples to $1.38M; OneRF ablation system launched
Product revenue $1.38M in Q2 2024, up from $466K in Q2 2023.
NeuroOne Medical Technologies starts limited commercial launch of OneRF Ablation System
OneRF System is FDA 510(k)-cleared for creating RF lesions in nervous tissue for functional neurosurgery.
NeuroOne Q1 revenue jumps to $978k; OneRF Ablation System receives FDA clearance
Product revenue $978k in Q1 fiscal 2024, up from $115k in Q1 2023.
NeuroOne Q4 product revenue $742K vs $69K YoY; net loss $3.1M; FDA clears OneRF Ablation System
Product revenue $742K (Q4) vs $69K YoY; full year $1.952M vs $171K.
NeuroOne receives FDA 510(k) clearance for OneRF Ablation System; plans H1 2024 launch
FDA 510(k) clearance for OneRF Ablation System to create RF lesions in nervous tissue for functional neurosurgical procedures.
NeuroOne Q3 FY2023 product revenue $630K, up from $32K; net loss $3.5M
Product revenue $630K in Q3 FY2023 vs $32K YoY; collaboration revenue $1.46M in 9M.
NeuroOne raises ~$5.2M net in registered direct offering of 6M shares at $1.00/share
Offered and sold 6,037,500 shares (including full overallotment) at $1.00 per share raising gross ~$6.04M.
NeuroOne Q2 product revenue surges to $466K; net loss $3.5M; Evo sEEG launched
Product revenue $466K in Q2 (vs $37K YoY); collaboration revenue $1.46M first half from Zimmer deal.
NeuroOne Q1 FY2023 net loss $1.7M; FDA cleared Evo sEEG electrode
Product revenue $115K (vs $34K YoY); collaboration revenue $1.46M from Zimmer agreement.
the Board announced that Christopher Volker, the Company’s Chief Operating Officer, will succeed Mr. McClurg as the Company’s Chief Financial Officer effective as of July 1, 2026.
On April 24, 2026, Ronald McClurg notified NeuroOne Medical Technologies Corporation (the "Company") of his intention to retire as the Company’s Chief Financial Officer.
Christopher R. Volker, age 52, has been appointed as the Chief Operating Officer of the Company, effective on November 10, 2023.
Max materiality 0.80 · Median 0.65 · Most common event other_material